+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

RANKL inhibition in the treatment of bone metastases

RANKL inhibition in the treatment of bone metastases

Current Opinion in Supportive and Palliative Care 2(3): 197-203

Bone metastases are common in patients with advanced malignancies and are associated with skeletal-related events, cancer progression, and death. Receptor activator of nuclear factor kappa beta ligand (RANKL) and its receptor, RANK, key mediators of osteoclast differentiation and function, play a pivotal role in bone destruction induced by metastatic bone tumors. The present review summarizes the contribution of RANKL to pathologic bone disease and presents early clinical data on RANKL inhibition in human metastatic cancer. RANKL/RANK interactions are essential for normal bone homeostasis. Binding of RANKL to RANK induces osteolytic bone resorption, a process that occurs in excess when tumor cells are present in bone. In cancer patients, increased tumor-induced osteolysis that is measurable using bone resorption markers can be used to monitor response to treatment or predict tumor progression. Denosumab, a novel, fully human monoclonal antibody specific to RANKL, suppresses bone resorption markers in patients with a variety of metastatic tumors and is being investigated in multiple clinical trials for the prevention and treatment of bone metastases. RANKL is an appropriate target to reduce the osteolytic bone damage caused by bone metastases. Clinical trials are ongoing to assess the safety and efficacy of denosumab for the treatment of bone resorption in patients with metastatic cancers.

(PDF emailed within 0-6 h: $19.90)

Accession: 055333179

Download citation: RISBibTeXText

PMID: 18685421

DOI: 10.1097/SPC.0b013e32830baac2

Related references

Advances in prevention and treatment of bone metastases in prostate cancer. Role of RANK/RANKL inhibition. Actas Urologicas Espanolas 37(5): 292-304, 2014

RANKL inhibition in bone metastases. Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica 141(1): 22-26, 2013

RANKL inhibition is an effective adjuvant for docetaxel in a prostate cancer bone metastases model. Prostate 68(8): 820-829, 2008

RANKL inhibition: clinical implications for the management of patients with multiple myeloma and solid tumors with bone metastases. Expert Opinion on Biological Therapy 9(4): 465-479, 2010

RANKL inhibition blocks osteolytic lesions and reduces skeletal tumor burden in models of non-small-cell lung cancer bone metastases. Journal of Thoracic Oncology 9(3): 345-354, 2014

Discovery of osteoclast differentiation factor, RANKL Inhibition of bone resorption by blocking RANKL-RANK signaling. Japanese Journal of Pharmacology 88(Supplement 1): 17P, 2002

Influence of RANKL inhibition on immune system in the treatment of bone diseases. Joint, Bone, Spine 75(1): 5-10, 2007

Alterations of the RANKL pathway in blood and bone marrow samples of prostate cancer patients without bone metastases. Prostate 73(2): 162-168, 2013

Assessment and clinical implications of RANK/RANKL/OPG pathway as markers of bone tumor progression in patients with NET harboring bone metastases. Biomarkers 18(2): 121-125, 2013

Regulation of RANKL might reduce bone metastases. Lancet. Oncology 7(5): 367-367, 2006

RANKL inhibition combined with tamoxifen treatment increases anti-tumor efficacy and prevents tumor-induced bone destruction in an estrogen receptor-positive breast cancer bone metastasis model. Breast Cancer Research and Treatment 135(3): 771-780, 2013

Additive bone-protective effects of anabolic treatment when used in conjunction with RANKL and tumor necrosis factor inhibition in two rat arthritis models. Arthritis and Rheumatism 52(5): 1604-1611, 2005

Comparable outcomes in fracture reduction and bone properties with RANKL inhibition and alendronate treatment in a mouse model of osteogenesis imperfecta. Osteoporosis International 23(3): 1141-1150, 2012

Bone metastases in gastric cancer follow a RANKL-independent mechanism. Oncology Reports 29(4): 1453-1458, 2013

miR-335 inhibits small cell lung cancer bone metastases via IGF-IR and RANKL pathways. Molecular Cancer Research 12(1): 101-110, 2014